



DRUG UTILIZATION REVIEW BOARD MEETING AGENDA

<u>Date</u>	<u>Time</u>	<u>Location</u>
October 18, 2023	10:00am – 3:00pm (CT)	Howerton State Office Building Conference Room 202 Jefferson City, MO 65109

Additional Meeting Details

The meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2634 926 8969

Meeting password: 4EtPt8kK87y

Join from a Video System/Application

Dial [26349268969](tel:26349268969) @stateofmo.webex.com

Or dial 173.243.2.68 and enter the meeting number.

Join from a Mobile Device (attendees only)

[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:25	Pharmacy Program/Budget Update	Elizabeth Short
10:25 – 10:35	AMP Cap Removal discussion and impact so far	Josh Moore
10:35 – 10:45	Review of Prior Authorization Meeting and Public Hearing	Josh Moore

Old Business

10:45 – 11:00	Discussion, Public Hearing and Decision	Josh Moore and Jennifer Colozza
	i. Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	
	ii. Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Criteria	
	a. Neuromyelitis Optica Spectrum Disorder (NMOSD) Clinical Edit	
	b. C5 Complement Inhibitors Clinical Edit	

New Business

11:00 – 11:15	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. Resource List	
	iv. PDL Agents	
	v. Prior Authorization	

Clinical and Fiscal Edit Review

11:15 – 12:15

Existing Criteria

Jennifer Colozza

- i. Alpelisib Clinical Edit
- ii. Emsam Clinical Edit
- iii. Entresto Clinical Edit
- iv. Immunoglobulins (IVIG and SCIG) Clinical Edit
- v. Narcolepsy Inhibitors Clinical Edit
- vi. Nuedexta Clinical Edit
- vii. Palforzia Clinical Edit
- viii. Parathyroid Hormone and Bone Resorption Suppression Related Agents Clinical Edit
- ix. Sickle Cell Disease Clinical Edit
- x. Spinal Muscular Atrophy (SMA) Clinical Edit
- xi. SSRI Step Therapy Clinical Edit
- xii. Transthyretin-Mediated Amyloidosis (ATTR) Clinical Edit
- xiii. Xcopri Clinical Edit

New Criteria or Revision of Existing Criteria

- i. Botulinum Toxin Clinical Edit
- ii. Diagnosis Code Required Policy Edit
- iii. Enzyme Deficiency, Select Agents Clinical Edit
- iv. Generalized Myasthenia Gravis Clinical Edit
- v. Lambert-Eaton Myasthenic Syndrome (LEMS) Clinical Edit
- vi. Psychotropic Medications Polypharmacy Clinical Edit
- vii. Ranolazine Clinical Edit
- viii. RSV Prophylaxis – Pediatric Clinical Edit
- ix. Skyclarys Clinical Edit
- x. SNRI Clinical Edit
- xi. Vyjuvek Clinical Edit

Break

12:15 – 12:30

Lunch

Preferred Drug List Edit Review

12:30 – 1:30

Existing Criteria

Josh Moore

- i. ACE Inhibitors/Calcium Channel Blocker Combinations PDL Edit
- ii. ADHD, Amphetamines Short Acting PDL Edit
- iii. ADHD, Methylphenidate Short Acting PDL Edit
- iv. ADHD, Non-Stimulants PDL Edit
- v. Angiotensin Receptor Blocker/Calcium Channel Blocker Combinations PDL Edit
- vi. Anticonvulsants, Rescue Agents PDL Edit
- vii. Antiplatelet Agents PDL Edit
- viii. Beta Adrenergic Blockers & Beta Adrenergic Blockers/Diuretic Combinations PDL Edit
- ix. Bone Ossification Agents PDL Edit
- x. Calcium Channel Blockers, Dihydropyridine PDL Edit
- xi. Direct Renin Inhibitors & Combinations PDL Edit
- xii. Electrolyte Depleting Agents, Phosphate Lowering PDL Edit
- xiii. Niacin Derivatives PDL Edit

- xiv. Proprotein Convertase Subtilisin Kexin type 9 (PCSK9) Inhibitors PDL Edit
- xv. Pulmonary Arterial Hypertension (PAH) Agents, Endothelin Receptor Antagonists (ETRAAs) PDL Edit
- xvi. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Inhaled PDL Edit
- xvii. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Injectable PDL Edit
- xviii. Pulmonary Arterial Hypertension (PAH) Agents, Prostacyclin Pathway Agonists, Oral PDL Edit
- xix. Triglyceride Lowering Agents PDL Edit

New Criteria or Revision of Existing Criteria

- i. ACE Inhibitors and ACE Inhibitors/Diuretic Combinations PDL Edit
- ii. ADHD, Amphetamines Long Acting PDL Edit
- iii. ADHD, Methylphenidate Long Acting PDL Edit
- iv. Angiotensin Receptor Blockers and Angiotensin Receptor Blocker/Diuretic Combinations PDL Edit
- v. Anticoagulants, Oral and Subcutaneous PDL Edit
- vi. Antihyperuricemic Agents PDL Edit
- vii. Benign Prostatic Hyperplasia Agents PDL Edit
- viii. Beta Adrenergic Agents, Short Acting PDL Edit
- ix. Bile Salt Agents PDL Edit
- x. Calcium Channel Blockers, Non-Dihydropyridine PDL Edit
- xi. Electrolyte Depleting Agents, Potassium Lowering PDL Edit
- xii. Homozygous Familial Hypercholesterolemia (HoFH) Agents PDL Edit
- xiii. Keratoconjunctivitis Agents PDL Edit
- xiv. Mineralocorticoid Receptor Antagonists (MRA) PDL Edit
- xv. Proton Pump Inhibitors (PPIs) PDL Edit
- xvi. Pulmonary Arterial Hypertension (PAH) Agents, Phosphodiesterase-5 (PDE5) and Soluble Guanylate Cyclase (SGC) Stimulators PDL Edit
- xvii. Statins (HMG-CoA Reductase Inhibitors) and Combinations PDL Edit
- xviii. Sympatholytics PDL Edit
- xix. Urea Cycle Disorder Agents PDL Edit

Program Utilization Information

1:30 – 1:45	Conduent Reports	John Crowley
	<ul style="list-style-type: none"> i. Call Center Statistics ii. Missouri SmartPA POS Transparency Report iii. “Top 25” Drugs by Cost/Claims 	
1:45 – 2:15	Conduent Retro DUR Report	Dimple Patel

Other Business/Closing Comments

2:15 – 2:30	Other Business	Josh Moore
-------------	----------------	------------

Executive Session

2:30 – 3:00	Data Analysis	Josh Moore
-------------	---------------	------------

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

Next Meeting: January 17, 2024

Meeting location and attendance options subject to change

Howerton Building, Room 202
615 Howerton Court
Jefferson City, MO 65109
Public attendance may be limited

Webex

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*

Missouri Board of Pharmacy approved for 5 hours (0.5 CEU) of pharmacy continuing education.

Webinar Attendees: In order to receive continuing education you must enter the webinar with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Utilization Review Board 10/18/23 CE Application". Incomplete submissions will not be processed.

In-Person Attendees: In order to receive continuing education you must sign in with your name as it appears on your Missouri Pharmacist License to earn credit. You must also email your name as it appears on your Missouri Pharmacist License, mailing address and Missouri pharmacist license number to MO HealthNet Pharmacy Scheduler (MHD.PHARMACYSCHEDULER@dss.mo.gov) within 24 hours after the conclusion of the meeting to earn credit with the subject "MHD Drug Utilization Review Board 10/18/23 CE Application". Incomplete submissions will not be processed.

CE credit is not submitted to the CPE Monitor.

Certificates will be emailed within 30 days of the meeting. You must save your certificates in case of audit by the Missouri Board of Pharmacy.

CE credit is only valid toward Missouri Board of Pharmacy licensure renewal.